Viatris Inc (VTRS)
Pharmaceutical Preparations · Pharmaceutical Preparations · NASDAQ
$16.25
+0.46%
Investingg Score
31.4 / 100
Sell
Business overview
- Gross margin of 35.1%
- Operating margin of -18.6%
- Revenue growth YoY of -3%
Margins are modest and operating loss combined with shrinking revenue suggest challenges to business quality.
Financial health
- Free cash flow margin of 13.5%
- Risk score of 70 (higher risk)
Positive cash flow margin is offset by a high risk score, indicating potential balance‑sheet concerns.
- Gross Margin
- 35.1%
- Operating Margin
- -18.6%
- Current Ratio
- 1.4x
- Debt / Equity
- 0.85
- Free Cash Flow (TTM)
- $1.9B
- Interest Coverage
- -6x
Valuation
- Forward P/E ratio of 6.97
- EV/EBITDA ratio of 3.56
Valuation multiples appear low, which could be attractive but may reflect the underlying earnings weakness.
- P/E (TTM)
- Data unavailable
- Forward P/E
- 7.0x
- Price / Sales
- 0.0x
- EV / EBITDA
- 3.6x
- FCF Yield
- Data unavailable
Key risks
- Revenue contraction
- Negative earnings growth
- Weak operating profitability
Market cap $0 · data as of 2026-08-20
Related stocks
Get the full interactive report
Technicals, earnings history, news, bull/base/bear scenarios, Ask the Stock, and more — free to start.
Analyze VTRS with Investingg AINot investment advice. Investingg AI summarizes public data and AI-generated analysis for informational purposes only.